BMY · Bristol Myers Squibb
AI read · Neutral
The AI's read
The results offer early signs that zola-cel may help people with progressive multiple sclerosis. But 42% of patients had cytokine release syndrome, a strong immune reaction, and 8% had neurotoxicity. A separate report described fatal septic pneumonia after the data cutoff without linking it to treatment, so this early study does not settle the treatment's promise.